Welcome, this website is intended for all international healthcare professionals in uro-oncology. By clicking the link below you are declaring and confirming that you are a healthcare professional.

You are here

Interview with Prof. Christopher Chapple - News from the EAU - The EAU's current activities in the field of oncology

News from the EAU - The EAU's current activities in the field of oncology - Prof. Chapple

Professor Christopher Chapple MD
EAU Secretary General
Department of Urology
Sheffield Teaching Hospital NHS Foundation Trust, UK

Video transcript:
Thank you very much for giving me the opportunity to speak today.  In the field of oncology, the EAU is very active and we are looking at this at many different levels.  Clearly oncology is a very important topic to urologists, for instance, prostate cancer, bladder cancer, and kidney cancer. 

Focusing on prostate cancer, for example, recently we have produced a White Paper for the European Commission on prostate cancer, and this was a project led by Professor von Poppel which was actually looking at all aspects of prostate cancer, producing a document which was very amenable and understandable to patients.   We are also working very closely with the pan-European group looking at the epidemiology of prostate cancer once screening has been used, the ERSPC study, and the EAU has funded that extensively over the last seven years, and we are going to continue to do that because we want to make sure we provide the best quality information to dictate practice in the context of prostate cancer.

Allied to the prostate cancer theme, obviously there is a lot of basic research going on and the surgical management of prostate cancer is extremely important to urologists.  So, recognising all this, we want to work closely with patients in this context, and in this aspect we deal very closely with the Europa Uomo Patient Group in achieving this aim.

We are also putting together an application to the European Commission and I, in my bit on the subject of prostate cancer, which is led by a colleague of mine working in Newcastle, Professor James Enda who is also responsible for our guidelines.  In this context, the EAU guidelines are the most up-to-date guidelines in the field of oncology, in urology, and as you know, most of them are updated at least every year, although some every two years.  So we feel that we have a very comprehensive overview of the subject.

Relating to cancer, I am pleased to announce that approximately 10 days ago, we were awarded a Reference Network as an Association of Urologists with the European Commission.  The Reference Network programme looks at aspects of rare diseases and conditions and in this context we have a cohort of people led by Professor Vijay Sangar who is the lead in the UK for NHS England for oncology in urology, and this is going to be dealing with rare cancers in the urological sector, for instance, penile cancer, retroperitoneal cancers and rare manifestations and conditions relating to other more common cancers.

So I hope you can see that we are really very aggressively, for the benefit of our patients, working with patient groups, reviewing the evidence base relating to the management of uro-operable cancer.  We are also progressing research in this area, and we are also looking at clinical practice with the reference network approach which is based on a multidisciplinary team approach which allows us to provide support and guidance to colleagues for the benefit of patients dealing with rare urological cancers.

Video summary:
Oncology is a very important topic for urologists and this video features Prof. Christopher Chapple, the General Secretary for EAU discussing the work EAU is doing in field of urological oncology. He discusses, for example, the EAU activities for prostate cancer such as the development of a white paper, funding epidemiological studies and basic research. Additionally, he also mentions the future projects of the EAU such as the development of a reference network of urologists to study rare urological cancers such as penile cancer. He, thus, highlights the multidisciplinary role of the EAU in terms of working with various patient groups, clinicians, researchers and governments to provide better care in urological oncology.